Dear visitor

It looks like you want to view this
website in a different language.

Please click here to view this website in English.
icon

KNCV is the largest NGO specialized in technical assistance for TB worldwide. Our work focuses on building strong and effective partnerships at global, regional and local level as we believe working with partners is crucial for lasting results. KNCV partners with governments, international agencies and private donors to strengthen TB control worldwide. We work to bring innovation to scale and deliver life-saving products and services to people in need of our care and expertise.

USAID Challenge TB

KNCV Tuberculosis Foundation has a longstanding relationship with the United States Agency for International Development (USAID). KNCV is the lead partner in the USAID project Challenge TB, the largest TB control project in the world. For the fourth time in a row we are leading this flagship project, which is implemented by a coalition consisting of, next to KNCV, American Thoracic Society (ATS), FHi 360, The Union, Japan Anti-Tuberculosis Association (JATA),  Management Sciences for Health (MSH), WHO Stop TB Department, PATH and Interactive Research and Development (IRD).

Improved TB/HIV Prevention & Care: “Building Models for the Future”

KNCV Tuberculosis Foundation often works as an enabler to bridge the gap in quality and availability between the public and private health care sectors. In partnership with HIVOS, PharmAccess and AFEW, KNCV is leading a project funded by the Ministry of Foreign Affairs in the Netherlands to provides a platform for productive dialogue between the private sector, civil society and government, with the goal to produce practical results while enabling partnerships.

IMPAACT4TB

For too long, interventions in high-burden countries have focused only on people with tuberculosis (TB) disease. The UNITAID-funded IMPAACT4TB project enables the use of a shorter preventive therapy regimen and helps reduce the chance of getting ill with TB for the most vulnerable people, such as children under five and people living with HIV.

The four-year UNITAID grant aims to ensure that people with latent tuberculosis infection (LTBI) – who are infected with the TB bacteria, but do not have symptoms and are not contagious – have access to new, shorter, and less toxic treatments to prevent they become sick with TB disease.

KNCV is delighted to partner with Aurum Institute, the Clinton Health Access Initiative, John Hopkins University and Stop TB Partnership’s Global Drug Facility. With Aurum Institute as the lead grantee, KNCV will apply its experience by providing technical assistance to scale up contact investigation for children and delivery of preventive treatment in children and PLWHIV.

Endowment funds

KNCV was founded in 1903 by a group of civil society organizations active in the Netherlands in the national fight against TB. KNCV was formed as a national association. Some of the local organizations still exist, although they are no longer actively involved in the treatment of TB in the Netherlands themselves. These organizations are nowadays Endowment funds supporting KNCV in its global fight against TB.

  • C. de Langen Stichting voor Mondiale Tuberculosebestrijding (SMT)
  • Stichting de ‘s- Gravenhaagse
  • Stichting Sonnevanck
  • Stichting Bakhuys Rooseboom

Partners and networks

KNCV Tuberculosis Foundation has longstanding collaborations with national TB control programs and associated partners in all regions of the world. At the global level, KNCV has over the years developed strong partnerships with many international organizations and networks such as WHO, the Global Fund and The Stop TB Partnership.

We serve as a member of many international advisory panels and committees such as STAG-TB,  Stop TB Partnership Coordinating Board, WHO Expert Committees, TB Europe Coalition and the Global taskforces on TB Impact Mesurement and Latent TB Infection.

In the Netherlands KNCV has a close working relationship with AIGHD (part of the Amsterdam Medical Center) and other academic institutes such as LUMC and Radboud University, working in the field of TB and TB/HIV research.